Specific subtypes of GABAA receptors mediate phasic and tonic forms of inhibition in hippocampal pyramidal neurons.
The main inhibitory neurotransmitter in the mammalian brain, GABA, mediates multiple forms of inhibitory signals, such as fast and slow inhibitory postsynaptic currents and tonic inhibition, by activating a diverse family of ionotropic GABA(A) receptors (GABA(A)Rs). Here, we studied whether distinct GABA(A)R subtypes mediate these various forms of inhibition using as approach mice carrying a point mutation in the alpha-subunit rendering individual GABA(A)R subtypes insensitive to diazepam without altering their GABA sensitivity and expression of receptors. Whole cell patch-clamp recordings were performed in hippocampal pyramidal cells from single, double, and triple mutant mice. Comparing diazepam effects in knock-in and wild-type mice allowed determining the contribution of alpha1, alpha2, alpha3, and alpha5 subunits containing GABA(A)Rs to phasic and tonic forms of inhibition. Fast phasic currents were mediated by synaptic alpha2-GABA(A)Rs on the soma and by synaptic alpha1-GABA(A)Rs on the dendrites. No contribution of alpha3- or alpha5-GABA(A)Rs was detectable. Slow phasic currents were produced by both synaptic and perisynaptic GABA(A)Rs, judged by their strong sensitivity to blockade of GABA reuptake. In the CA1 area, but not in the subiculum, perisynaptic alpha5-GABA(A)Rs contributed to slow phasic currents. In the CA1 area, the diazepam-sensitive component of tonic inhibition also involved activation of alpha5-GABA(A)Rs and slow phasic and tonic signals shared overlapping pools of receptors. These results show that the major forms of inhibitory neurotransmission in hippocampal pyramidal cells are mediated by distinct GABA(A)Rs subtypes.
Prenosil
George A
GA
University of Zurich, Institute of Pharmacology and Toxicology, Zurich, Switzerland.
Schneider Gasser
Edith M
EM
Rudolph
Uwe
U
Keist
Ruth
R
Fritschy
Jean-Marc
JM
Vogt
Kaspar E
KE
D000818:Animals; D003627:Data Interpretation, Statistical; D003975:Diazepam / Q000494:pharmacology; D004594:Electrophysiology; D005071:Evoked Potentials / Q000502:physiology; D019706:Excitatory Postsynaptic Potentials / Q000502:physiology; D005838:Genotype; D006624:Hippocampus / Q000166:cytology / Q000502:physiology*; D006993:Hypnotics and Sedatives / Q000494:pharmacology; D007150:Immunohistochemistry; D066298:In Vitro Techniques; D051379:Mice; D008822:Mice, Transgenic; D018408:Patch-Clamp Techniques; D010721:Phosphinic Acids / Q000494:pharmacology; D017354:Point Mutation / Q000502:physiology; D011412:Propanolamines / Q000494:pharmacology; D021122:Protein Subunits / Q000235:genetics / Q000378:metabolism; D017966:Pyramidal Cells / Q000502:physiology*; D011963:Receptors, GABA-A / Q000235:genetics / Q000378:metabolism / Q000502:physiology*
C546241:Gabra1 protein, mouse; C493920:Gabra2 protein, mouse; D006993:Hypnotics and Sedatives; D010721:Phosphinic Acids; D011412:Propanolamines; D021122:Protein Subunits; D011963:Receptors, GABA-A; C085075:CGP 55845A; D003975:Diazepam